Vivos Inc., a publicly traded entity on the OTC Bulletin Board, has recently come under scrutiny due to its financial performance and market valuation. As of February 8, 2026, the company’s shares closed at $0.069, a figure that underscores the volatility and challenges faced by the firm over the past year. The stock has experienced significant fluctuations, reaching a 52-week high of $0.1739 on February 18, 2025, and a low of $0.0425 on August 13, 2025. This volatility is indicative of the market’s uncertainty regarding Vivos’ future prospects.
The company’s market capitalization stands at $31.8 million, a modest figure that reflects its current standing in the market. However, the financial metrics paint a more concerning picture. Vivos Inc. reports a negative price-to-earnings (P/E) ratio of -9.57 and a price-to-book (P/B) ratio of -4.43581. These ratios are critical indicators of the company’s financial health and market perception. A negative P/E ratio suggests that the company is not generating positive earnings, which is a red flag for investors seeking profitable ventures. Similarly, the negative P/B ratio indicates that the market values the company’s equity below its book value, further emphasizing the lack of confidence in its financial stability and growth potential.
The recent update from Vivos Inc. on February 3, 2026, regarding its human therapy progress in India, has done little to alleviate investor concerns. While the company continues to pursue advancements in its therapeutic endeavors, the financial metrics suggest that these efforts have yet to translate into tangible profitability or market confidence. The persistent trading below both earnings and book values highlights a disconnect between the company’s operational activities and its financial outcomes.
In conclusion, Vivos Inc. finds itself in a precarious position, grappling with market skepticism and financial underperformance. The negative P/E and P/B ratios serve as stark reminders of the challenges the company faces in achieving profitability and regaining investor trust. As Vivos navigates its path forward, it must address these fundamental issues to restore confidence and stabilize its market valuation. The road ahead is fraught with challenges, and only through strategic adjustments and demonstrable progress can Vivos hope to reverse its current trajectory.
